AAAAAA

   
Results: 1-19 |
Results: 19
Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up
Authors: Alexander, KP Newby, LK Hellkamp, AS Harrington, RA Peterson, ED Kopecky, S Langer, A O'Gara, P O'Connor, CM Daly, RN Califf, RM Khan, S Fuster, V
Citation: Kp. Alexander et al., Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up, J AM COL C, 38(1), 2001, pp. 1-7
Bedside multimarker testing for risk stratification in chest pain units: The chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study - Response
Authors: Newby, LK Kaplan, AL Tuttle, RH McNulty, SE Ohman, EM Storrow, AB Gibler, WB
Citation: Lk. Newby et al., Bedside multimarker testing for risk stratification in chest pain units: The chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study - Response, CIRCULATION, 104(22), 2001, pp. E125-E126
Single nucleotide polymorphisms in multiple novel thrombospondin genes maybe associated with familial premature myocardial infarction
Authors: Topol, EJ McCarthy, J Gabriel, S Moliterno, DJ Rogers, WJ Newby, LK Freedman, M Metivier, J Cannata, R O'Donnell, CJ Kottke-Marchant, K Murugesan, G Plow, EF Stenina, O Daley, GQ
Citation: Ej. Topol et al., Single nucleotide polymorphisms in multiple novel thrombospondin genes maybe associated with familial premature myocardial infarction, CIRCULATION, 104(22), 2001, pp. 2641-2644
Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status - The PARAGON-B troponin T substudy
Authors: Newby, LK Ohman, EM Christenson, RH Moliterno, DJ Harrington, RA White, HD Armstrong, PW Van de Werf, F Pfisterer, M Hasselblad, V Califf, RM Topol, EJ
Citation: Lk. Newby et al., Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status - The PARAGON-B troponin T substudy, CIRCULATION, 103(24), 2001, pp. 2891-2896
Bedside multimarker testing for risk stratification in chest pain units - The chest pain evaluation by creatine Kinase-MB, myoglobin, and troponin I (CHECKMATE) study
Authors: Newby, LK Storrow, AB Gibler, WB Garvey, JL Tucker, JF Kaplan, AL Schreiber, DH Tuttle, RH McNulty, SE Ohman, M
Citation: Lk. Newby et al., Bedside multimarker testing for risk stratification in chest pain units - The chest pain evaluation by creatine Kinase-MB, myoglobin, and troponin I (CHECKMATE) study, CIRCULATION, 103(14), 2001, pp. 1832-1837
The role of the troponins and other markers of myocardial necrosis in riskstratification
Authors: Newby, LK Ohman, EM Christenson, RH
Citation: Lk. Newby et al., The role of the troponins and other markers of myocardial necrosis in riskstratification, ACUTE CORONARY SYNDROMES, SECOND EDITION, 2001, pp. 329-372
Oral glycoprotein IIb/IIIa antagonists: New insights from the SYMPHONY trial
Authors: McGuire, DK Newby, LK
Citation: Dk. Mcguire et Lk. Newby, Oral glycoprotein IIb/IIIa antagonists: New insights from the SYMPHONY trial, J THROMB TH, 10(2), 2000, pp. 111-119
A randomized comparison of sibrafiban, an oral glycoprotein (GP) IIb/IIIa receptor antagonist, with and without aspirin versus aspirin after acute coronary syndromes (ACS): Results of the second symphony trial
Authors: Newby, LK
Citation: Lk. Newby, A randomized comparison of sibrafiban, an oral glycoprotein (GP) IIb/IIIa receptor antagonist, with and without aspirin versus aspirin after acute coronary syndromes (ACS): Results of the second symphony trial, J AM COL C, 36(1), 2000, pp. 319-320
Troponins in pericarditis: implications for diagnosis and management of chest pain patients
Authors: Newby, LK Ohman, EM
Citation: Lk. Newby et Em. Ohman, Troponins in pericarditis: implications for diagnosis and management of chest pain patients, EUR HEART J, 21(10), 2000, pp. 798-800
Randomisation in the SYMPHONY trial - Reply
Authors: Newby, LK Bhapkar, MV Lee, KL Califf, RM
Citation: Lk. Newby et al., Randomisation in the SYMPHONY trial - Reply, LANCET, 356(9240), 2000, pp. 1521-1522
Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial
Authors: Topol, CE Califf, RM Simes, RJ Van de Werf, F Diaz, R Paolasso, E Aylward, PE Keech, A Klein, W Piegas, L Tomov, I Armstrong, PW Widimsky, P Grande, P Halinen, M Vahanian, A Neuhaus, K Dimas, AP Preda, I Kristinsson, A Tzivoni, D Ardissino, D White, HD Madsen, S Sugrue, D Sadowski, Z Seabra-Gomes, R Apetrei, E Dalby, A Betriu, A Pfisterer, M Verheugt, F Fox, K Bates, ER Gibler, WB Granger, CB Harrington, RA Hochman, JS Holmes, DR Kleiman, NS Lee, KL Moliterno, DJ Newby, LK Ohman, EM Califf, R Newby, K Zillman, L Lee, K Lemons, P McCourt, B Campbell, C Tardiff, B Snapp, J Bassett, K Hodgson, P Hannan, K Kandzari, L Hawkins, S Hinman-Smith, E McDougal, M Raffetto, K Thompson, D Wehrle, T Ange, C Brown, R Grissom, G Heuckel, M McCall, J Pennachi, W Spychala, M Veasey, S Pullium, M Journey, T Quintero, K Mark, D Davidson-Ray, L Diner, L Nelson, C Sowers, C Webb, G Young, M Bhapkar, M Pacchiana, C Sparapani, R Tuttle, R Weaver, D Borzak, S Douthat, L Topol, E Moliterno, D Konczos, L Baishnab, R Baishnab, R Bakos, A Blashford, L Bratsch, J Brown, K Cadorini, E Carlson, J Clemmons, P DelValle, M Drabik, M Fu, G Gates, K Gibson, Y Heil, L Hill, N Klancar, R McHale, B Montague, E Pasca, N Pergi, L Randall, R Rosso, R Sankovich, K Smith, D Wisniewski, L Witkowski, M Zovkic, V Alexander, K Bhatt, D Brener, S Campbell, L Cho, L Cole, C Deedy, M Foody, J Gassler, J Ghaffari, S Haas, G Kapadia, S Lauer, M Lauer, MS Lincoff, M Lutton, S Marso, S Mukherjee, D Patel, V Penn, M Robbins, M Roe, M Sila, C Thamilarasan, M Wagner, G Armstrong, P Bestilny, S Van de Werf, F Budts, W Graux, S Luyten, A Simes, J Keech, A Kava, M Bower, T Chan, S Crampton, L Monro, C Nayak, M Parente, G Riley, V Wilton, D Aylward, P Dolan, S Thomas, C White, H Scott, M Frye, R Alpert, J Bertrand, M Ryan, T Fisher, L Asarch, L Smith, M Lim, L Bokslag, M Chiu, P Chung, J Collins, S Dougherty, C Guimaraes, D Hakim, Z Mathieson, J Montgomery, L Novotny, B Steiner, B Wittke, B
Citation: Ce. Topol et al., Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial, LANCET, 355(9201), 2000, pp. 337-345
Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation
Authors: Alexander, JH Sparapani, RA Mahaffey, KW Deckers, JW Newby, LK Ohman, EM Corbalan, R Chierchia, SL Boland, JB Simoons, ML Califf, RM Topol, EJ Harrington, RA
Citation: Jh. Alexander et al., Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation, J AM MED A, 283(3), 2000, pp. 347-353
Cost effectiveness of early discharge after uncomplicated acute myocardialinfarction.
Authors: Newby, LK Eisenstein, EL Califf, RM Thompson, TD Nelson, CL Peterson, ED Armstrong, PW Van de Werf, F White, HD Topol, EJ Mark, DB
Citation: Lk. Newby et al., Cost effectiveness of early discharge after uncomplicated acute myocardialinfarction., N ENG J MED, 342(11), 2000, pp. 749-755
Comparison of cardiac troponin T versus creatine kinase-MB for risk stratification in a chest pain evaluation unit
Authors: Newby, LK Kaplan, AL Granger, BB Sedor, F Califf, RM Ohman, EM
Citation: Lk. Newby et al., Comparison of cardiac troponin T versus creatine kinase-MB for risk stratification in a chest pain evaluation unit, AM J CARD, 85(7), 2000, pp. 801-805
Relation of temporal creatine kinase-MB release and outcome after thrombolytic therapy for acute myocardial infarction
Authors: Christenson, RH Vollmer, RT Ohman, EM Peck, S Thompson, TD Duh, SH Ellis, SG Newby, LK Topol, EJ Califf, RM
Citation: Rh. Christenson et al., Relation of temporal creatine kinase-MB release and outcome after thrombolytic therapy for acute myocardial infarction, AM J CARD, 85(5), 2000, pp. 543-547
Cardiac marker testing: Where should we focus?
Authors: Newby, LK
Citation: Lk. Newby, Cardiac marker testing: Where should we focus?, AM HEART J, 140(3), 2000, pp. 351-353
Cardiac markers: point of care testing
Authors: Hudson, MP Christenson, RH Newby, LK Kaplan, AL Ohman, EM
Citation: Mp. Hudson et al., Cardiac markers: point of care testing, CLIN CHIM A, 284(2), 1999, pp. 223-237
Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: Study design of the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events post-acute cOroNary syndromes (SYMPHONY) trial
Authors: Newby, LK
Citation: Lk. Newby, Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: Study design of the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events post-acute cOroNary syndromes (SYMPHONY) trial, AM HEART J, 138(2), 1999, pp. 210-218
The chest-pain unit - Ready for prime time?
Authors: Newby, LK Mark, DB
Citation: Lk. Newby et Db. Mark, The chest-pain unit - Ready for prime time?, N ENG J MED, 339(26), 1998, pp. 1930-1932
Risultati: 1-19 |